{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:25:12Z","timestamp":1793957112722,"version":"4.8.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hlc.2023.11.027","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T12:42:43Z","timestamp":1712061763000},"page":"420-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["2024 Australia\u2013New Zealand Expert Consensus Statement on Cardiac Amyloidosis"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-0758","authenticated-orcid":false,"given":"Nicole K.","family":"Bart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-9856","authenticated-orcid":false,"given":"Diane","family":"Fatkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-1867","authenticated-orcid":false,"given":"James L.","family":"Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Korczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasib","family":"Sidiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.J.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-7780","authenticated-orcid":false,"given":"Liza","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2023.11.027_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","article-title":"Amyloidosis","volume":"57","author":"Pepys","year":"2006","journal-title":"Annu Rev Med"},{"issue":"38","key":"10.1016\/j.hlc.2023.11.027_bib4","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.1074\/jbc.M116.736736","article-title":"Cell Damage in Light Chain Amyloidosis: Fibril internalization, toxicity and cell-mediated seeding","volume":"291","author":"Marin-Argany","year":"2016","journal-title":"J\u00a0Biol Chem"},{"issue":"23","key":"10.1016\/j.hlc.2023.11.027_bib5","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A\u00a0Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib6","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"10.1016\/j.hlc.2023.11.027_bib7","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.hlc.2023.11.027_bib8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.hlc.2023.11.027_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nn1335","article-title":"Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches","volume":"7","author":"Tsai","year":"2004","journal-title":"Nat Neurosci"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib11","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"14","key":"10.1016\/j.hlc.2023.11.027_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ehj.2004.04.014","article-title":"Atrial amyloidosis and atrial fibrillation: a gender-dependent \"arrhythmogenic substrate\"?","volume":"25","author":"Goette","year":"2004","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib13","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s12350-020-02152-x","article-title":"Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation","volume":"28","author":"Cuscaden","year":"2021","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.hlc.2023.11.027_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","article-title":"Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population","volume":"270","author":"Mohamed-Salem","year":"2018","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"38","key":"10.1016\/j.hlc.2023.11.027_bib16","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.027_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circulation Cardiovasc Imaging"},{"issue":"38","key":"10.1016\/j.hlc.2023.11.027_bib19","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cardfail.2017.12.005","article-title":"Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis","volume":"24","author":"Papoutsidakis","year":"2018","journal-title":"J\u00a0Card Fail"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/joim.13222","article-title":"Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis","volume":"289","author":"Eldhagen","year":"2021","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/joim.13200","article-title":"Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype","volume":"289","author":"Cappelli","year":"2021","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.16000","article-title":"The epidemiology of amyloidosis in Queensland, Australia","volume":"186","author":"Wisniowski","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0046-8177(93)90239-D","article-title":"Isolated atrial amyloidosis: a clinicopathologic study indicating increased prevalence in chronic heart disease","volume":"24","author":"Looi","year":"1993","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib27","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hlc.2023.11.027_bib28","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCIMAGING.113.001396","article-title":"How to image cardiac amyloidosis","volume":"7","author":"Falk","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0002-9149(83)80139-8","article-title":"Myocardial texture characterization by two-dimensional echocardiography","volume":"51","author":"Bhandari","year":"1983","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9149(87)90948-9","article-title":"Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis","volume":"59","author":"Falk","year":"1987","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.hlc.2023.11.027_bib33","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.hlc.2023.11.027_bib34","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0735-1097(89)90254-4","article-title":"Doppler characterization of left ventricular diastolic function in cardiac amyloidosis","volume":"13","author":"Klein","year":"1989","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.hlc.2023.11.027_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0002-9149(02)02277-4","article-title":"Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis","volume":"89","author":"Koyama","year":"2002","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.027_bib37","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ehjci\/jes009","article-title":"Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study","volume":"13","author":"Bellavia","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib38","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/ejechocard\/jer289","article-title":"Right ventricular function in AL amyloidosis: characteristics and prognostic implication","volume":"13","author":"Cappelli","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.027_bib39","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1253\/circj.CJ-16-0364","article-title":"Left atrial morphology, size and function in patients with transthyretin cardiac amyloidosis and primary hypertrophic cardiomyopathy - Comparative Strain Imaging Study","volume":"80","author":"de Gregorio","year":"2016","journal-title":"Circ J"},{"issue":"21","key":"10.1016\/j.hlc.2023.11.027_bib40","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis: JACC Review Topic of the Week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13449","article-title":"A\u00a0simple echocardiographic score to rule out cardiac amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib44","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jcmg.2020.08.035","article-title":"Left ventricular mass-to-strain ratio predicts cardiac amyloid subtype","volume":"14","author":"Geenty","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.hlc.2023.11.027_bib46","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1515\/cclm-2013-0361","article-title":"Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis","volume":"51","author":"Mollee","year":"2013","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.hlc.2023.11.027_bib47","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1515\/cclm-2015-0799","article-title":"Comparison of Freelite\u2122 and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis","volume":"54","author":"Kennard","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.hlc.2023.11.027_bib49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib50","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib51","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib52","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J\u00a0Nucl Cardiol"},{"issue":"24","key":"10.1016\/j.hlc.2023.11.027_bib53","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib54","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib56","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1 Pt 1","key":"10.1016\/j.hlc.2023.11.027_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib59","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala","year":"2020","journal-title":"J\u00a0Nucl Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib62","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and Extracellular Volume in Transthyretin Amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hlc.2023.11.027_bib63","article-title":"Assessment of treatment response in cardiac AL amyloidosis using CMR mapping-results at 3 months, 6 months and 1 year post-chemotherapy","volume":"138","author":"Martinez-Naharrro","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib64","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib65","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s12350-020-02455-z","article-title":"Addendum to ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"28","author":"Dorbala","year":"2021","journal-title":"J\u00a0Nucl Cardiol"},{"issue":"9","key":"10.1016\/j.hlc.2023.11.027_bib66","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"18","key":"10.1016\/j.hlc.2023.11.027_bib67","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib68","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1007\/s12325-022-02139-9","article-title":"Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: An expert opinion and consensus on best practice in Ireland and the UK","volume":"39","author":"Gillmore","year":"2022","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/HCO.0000000000000841","article-title":"Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies","volume":"36","author":"Alreshq","year":"2021","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib71","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","article-title":"Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus","volume":"15","author":"Grandis","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib72","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1309\/PFUGHBX0TY20E08U","article-title":"Bone marrow core biopsy specimens in AL (primary) amyloidosis: a morphologic and immunohistochemical study of 100 cases","volume":"120","author":"Swan","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hlc.2023.11.027_bib73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2017.11.001","article-title":"Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis","volume":"72","author":"Garcia","year":"2018","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.acthis.2006.03.010","article-title":"Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it","volume":"108","author":"Linke","year":"2006","journal-title":"Acta Histochem"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib75","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients","volume":"119","author":"Schonland","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib76","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","article-title":"A\u00a0comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue","volume":"68","author":"Gilbertson","year":"2015","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.hlc.2023.11.027_bib77","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12014-016-9133-x","article-title":"Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry","volume":"13","author":"Mollee","year":"2016","journal-title":"Clin Proteomics"},{"issue":"9","key":"10.1016\/j.hlc.2023.11.027_bib78","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"30","key":"10.1016\/j.hlc.2023.11.027_bib79","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib80","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.hlc.2023.11.027_bib81","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.hlc.2023.11.027_bib82","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","article-title":"Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia","volume":"104","author":"Dittrich","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib83","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.027_bib85","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.hlc.2023.11.027_bib86","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"11","key":"10.1016\/j.hlc.2023.11.027_bib88","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hlc.2023.11.027_bib89","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2020.12.009","article-title":"Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic","volume":"233","author":"Vaishnav","year":"2021","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib90","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"9766","key":"10.1016\/j.hlc.2023.11.027_bib91","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib92","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/13506129.2021.1966624","article-title":"Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure","volume":"28","author":"Vergaro","year":"2021","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.hlc.2023.11.027_bib93","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib94","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib95","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.hlc.2023.11.027_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2019.102590","article-title":"Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"222","author":"Gonz\u00e1lez-Duarte","year":"2019","journal-title":"Auton Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2023.11.027_bib97","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10286-019-00623-x","article-title":"Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management","volume":"29","author":"Palma","year":"2019","journal-title":"Clin Auton Res"},{"issue":"9","key":"10.1016\/j.hlc.2023.11.027_bib98","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.027_bib99","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.cjca.2019.11.039","article-title":"Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment","volume":"36","author":"Cheung","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hlc.2023.11.027_bib101","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin use in cardiac amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.hlc.2023.11.027_bib102","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.hlc.2023.11.027_bib103","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib104","article-title":"Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis","volume":"48","author":"Bukhari","year":"2023","journal-title":"CurrProbl Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"14","key":"10.1016\/j.hlc.2023.11.027_bib106","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2023.11.027_bib107","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1097\/TP.0000000000002240","article-title":"Outcomes after cardiac transplant for wild type transthyretin amyloidosis","volume":"102","author":"Rosenbaum","year":"2018","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2023.11.027_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10286-019-00630-y","article-title":"Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review","volume":"29","author":"Gonzalez-Duarte","year":"2019","journal-title":"Clin Auton Res"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib110","first-page":"528","article-title":"Pathophysiology, functional assessment and prognostic implications of nutritional disorders in systemic amyloidosis","volume":"12","author":"Dongiglio","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib111","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jgh.13996","article-title":"Systemic amyloidosis with gastrointestinal involvement: Diagnosis from endoscopic and histological views","volume":"33","author":"Iida","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/13506129.2022.2035354","article-title":"Amyloidosis from the patient perspective: the French daily impact of amyloidosis study","volume":"29","author":"Damy","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib113","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/13506129.2018.1428795","article-title":"Psychopathological dimensions in subjects with hereditary ATTR V30M amyloidosis and their relation with life events due to the disease","volume":"25","author":"Lopes","year":"2018","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hlc.2023.11.027_bib116","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.027_bib117","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib118","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2019.1643714","article-title":"A\u00a0comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy","volume":"26","author":"Huber","year":"2019","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.hlc.2023.11.027_bib119","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.hlc.2023.11.027_bib121","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.027_bib122","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib123","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hlc.2023.11.027_bib124","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hlc.2023.11.027_bib125","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.2147\/DDDT.S96893","article-title":"Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study","volume":"9","author":"aus dem Siepen","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.027_bib126","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2023.11.027_bib127","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.027_bib128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis","volume":"25","author":"Karlstedt","year":"2019","journal-title":"J\u00a0Card Fail"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.027_bib129","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624001239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624001239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:17:04Z","timestamp":1714609024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950624001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1443950624001239"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2023.11.027","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2024 Australia\u2013New Zealand Expert Consensus Statement on Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2023.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}